欧洲围术期静脉血栓栓塞预防指南:存在凝血障碍及严重围术期出血后的患者
该指南针对存在遗传性出血性疾病或严重围术期出血后的患者,提出了围术期静脉血栓栓塞预防的推荐意见。推荐个体化评估血栓风险与出血风险的平衡,反对对大型手术的遗传性出血性疾病患者常规术后药物预防,并给出了直接口服抗凝药肾功能监测、低分子肝素减量使用等具体建议。
要点
- 遗传性出血性疾病患者术前应个体化评估静脉血栓栓塞风险,权衡抗凝出血风险。
- 血友病A和B患者大型手术后不推荐常规药物血栓预防。
- 严重胃肠道出血后恢复华法林应至少延迟7天。
核心结论
- 对遗传性出血性疾病手术患者,应个体化评估静脉血栓栓塞风险并平衡抗凝相关出血风险。
- 大型手术的遗传性出血性疾病患者,尤其血友病A和B,不推荐常规术后药物血栓预防。
研究设计与样本
- 欧洲麻醉学学会指南,针对存在凝血障碍及严重围术期出血患者的围术期静脉血栓栓塞预防。
主要发现
- 推荐根据手术和麻醉性质、出血性疾病类型和严重程度、年龄、BMI、血栓史、恶性肿瘤及其他高危合并症评估静脉血栓栓塞风险(Grade 1C)。
- 对大型手术的遗传性出血性疾病患者,尤其血友病A和B,推荐反对常规术后药物血栓预防(Grade 1B)。
关键数值与推荐
- 每次启动直接口服抗凝药前应评估肾小球滤过率,并至少每年一次或更频繁(Grade 1C)。
- 短暂严重血小板减少(<50 × 10 l)期间可相对安全使用减量低分子肝素(Grade 2C)。
- 中或重度血小板减少患者可监测抗Xa水平调整低分子肝素剂量(Grade 2C)。
- 严重胃肠道出血后恢复华法林应至少延迟7天(Grade 2C)。
- 血栓高危且术后出血高危患者,术后当晚及术后第一天给予减量直接口服抗凝药是良好实践(Grade 2B)。
临床怎么用
- 术前对遗传性出血性疾病患者进行个体化静脉血栓栓塞风险评估。
- 大型手术的血友病A和B患者避免常规术后药物血栓预防。
- 使用直接口服抗凝药前及每年评估肾功能,术后恢复治疗前再次评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
: In patients with inherited bleeding disorders undergoing surgery, we recommend assessment of individual risk for venous thromboembolism, taking into account the nature of the surgery and anaesthetic, type and severity of bleeding disorder, age, BMI, history of thrombosis, the presence of malignancy and other high-risk comorbidities. Venous thromboembolism risk should be balanced against the increased bleeding risk associated with anticoagulant use in patients with known bleeding disorders (Grade 1C). In these patients undergoing major surgery, we recommend against routine postoperative use of pharmacological thromboprophylaxis, especially for patients with haemophilia A and B (Grade 1B). Glomerular filtration rate should be assessed before initiation of each direct oral anticoagulant, and also at least once a year or more frequently as needed, such as postoperatively before the resumption of therapeutic direct oral anticoagulant administration, when it is suspected that renal function could decline or deteriorate (Grade 1C). Reduced dosages of low molecular weight heparins may be used relatively safely during transient severe (<50 × 10 l) thrombocytopaenia (Grade 2C). Monitoring of anti-Xa levels may be used to adjust the doses of low molecular weight heparin in patients with moderate or severe thrombocytopaenia (Grade 2C). The delay between major gastrointestinal bleeding and resuming warfarin should be at least 7 days (Grade 2C). For patients at a high risk of thromboembolism and with a high bleeding risk after surgery, we consider that administering a reduced dose of direct oral anticoagulant on the evening after surgery and on the following day (first postoperative day) after surgery is a good practice (Grade 2B).
引用
- Ahmed A, Kozek-Langenecker S, Mullier F, et al. European guidelines on perioperative venous thromboembolism prophylaxis: Patients with preexisting coagulation disorders and after severe perioperative bleeding. Eur J Anaesthesiol. 2018. PMID: 29112549. doi:10.1097/EJA.0000000000000725
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。